Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Asbestos exposure: Challenges for Australian clinicians

Anxiety and the inability to reduce MM risk following exposure or to halt progression of established asbestosis result in significant health care problems

Research

Schizophrenia Spectrum Disorders and Autism Spectrum Disorder

We examine the level of comorbidity found between Autism spectrum disorder and Schizophrenia spectrum disorders at a clinical and trait level

Research

Characterization of G2P[4] rotavirus strains causing outbreaks of gastroenteritis in the Northern Territory, Australia, in 1999, 2004 and 2009

Outbreaks of rotavirus diarrhea cause a large disease burden in the Alice Springs region of the Northern Territory, Australia.

Research

House dust mite induced lung inflammation does not alter circulating vitamin D levels

We hypothesized that allergic inflammation decreases the level of circulating 25(OH)D and tested this using a mice model of house dust mite (HDM) induced...

Research

Peri-operative adverse respiratory events in children

We screened for risk factors from children's and their families' histories, and assessed the usefulness of common markers of allergic sensitisation of the...

Research

Parental Tdap boosters and infant pertussis: a case-control study

Case households had fewer immunized mothers (22% vs 32%) or fathers (20% vs 31%) but were more likely to include additional and older children. After...

Research

Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents

Staphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

News & Events

Nine out of ten young people in detention found to have severe neuro-disability

Nine out of ten incarcerated youth examined by The Kids researchers as part of a ground-breaking study had some form of neuro-disability.